PainReform Ltd. (NASDAQ:PRFX) experienced a decline Tuesday following the company's announcement of a warrant exercise. The company revealed it had entered into definitive agreements to exercise certain outstanding warrants, which generated gross proceeds of approximately $1.58 million.
What To Know: These warrants, originally issued in December 2023 and April 2024, were initially priced at $4.80 per share, but PainReform reduced the exercise price to $1.60 per share to encourage the transaction.
As part of the agreement, the company also issued new unregistered warrants for the purchase of up to 1,978,600 ordinary shares, with the same $1.60 per share exercise price. The proceeds from the warrant exercise are intended to be used for general corporate purposes, potentially signaling a need for liquidity or operational funding.
PRFX Price Action: PainReform shares were by 32.1% at $1.08 according to Benzinga pro.
See Also:
Image Via PainReform Inc.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
